Skip to main content
. 2025 Feb 10;10(6):5686–5698. doi: 10.1021/acsomega.4c08645

Figure 2.

Figure 2

Antiproliferative activity of compounds on cancer and normal cells. (A, B) BEAS-2B, A549, and H1795 cells were subjected to treatment with compounds 38 and 45 at various concentrations for 72 h. Cell viability was assessed using an MTT assay. (C, D) BEAS-2B, A549, and H1795 cells were subjected to treatment with doxorubicin and paclitaxel at various concentrations for 72 h. Cell viability was assessed using the MTT assay. n = 3.